Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.
Episodes
136 episodes
Can RNA drugs solve the obesity epidemic?
Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment.Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets...
•
29:56
Reversing cancer mechanisms to fight back against solid tumors
CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differe...
•
21:24
Targeting the dark genome to develop new therapies to fight obesity
In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity.The company’s lead candidate, HTX-001, is making progress...
•
32:32
Can Tumor Activated Therapy kill solid tumors?
Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo sci...
•
31:22
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed
This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.While there weren’t necessarily many financial blockbusters, there were plenty ...
•
19:57
Venture capital co-creation: The next big thing in biotech investment?
Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund.Initiate Ventures is shaking up the traditional venture capital ...
•
37:22
Developing non-opioid pain drugs
Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, injectable pain relief solutions....
•
33:01
[Rebroadcast] The power of natural killer cells
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!On this podcast, we speak to Artiva Bio...
•
28:59
Looking at 2025 biotech trends with SoftBank Vision Fund
Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund.Softbank Vision Fund is the world’s largest technology-focused investment fund, with $166bn assets un...
•
39:04
Finding new treatments for peanut allergy
There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens.IgGenix, a clinical-stage immunology bio...
•
31:06
Cracking the code of biotech valuations
ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava.The company helps its corporate clients with their product strategy, in- and out-licensing efforts, including a...
•
37:43
Can biotech beat mosquito-borne diseases?
Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever.Backed by a multi-million-dollar investment from the Gates Foundation, S...
•
35:59
Could antigen modulation address autoimmune diseases?
Immunology is a key area in biotech and biopharma, both in terms of R&D and sales.However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle.To have an immuno...
•
24:04
Beyond profits: The Bill & Melinda Gates MRI's mission to combat neglected diseases
The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantia...
•
38:10
How to succeed as a woman in biotech
This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire...
•
34:12
The immunometabolism landscape
Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and ...
•
30:13
Biotech beyond earth: The future of medicine in space
LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease.Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an a...
•
39:01
The future of gene therapy
Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as
•
33:25
Bispecific ADCs: the next generation of cancer treatments
Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge.
•
29:45
Targeting telomerase to disrupt cancer
Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosom...
•
26:30
Harnessing the body’s natural targeted protein degradation system to treat diseases
C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-st...
•
34:04
Estonia's biobank: Is this the first large-scale personalized medicine initiative?
Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank.The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adapt...
•
32:15
Targeting inflammation: A revolution in disease treatment
Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.NLRP3 inflammasome-induced inflammation is at the root of nearly all disease...
•
43:10